Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amarin Corporation Plc    AMRN

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Amarin : Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology

share with twitter share with LinkedIn share with facebook
share via e-mail
06/11/2014 | 01:11pm CET

LONDON, June 11, 2014 /PRNewswire/ --

The US markets on Tuesday, June 10, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,945.92, up 0.02% and the NASDAQ Composite closed at 4,338.00, up 0.04%. The S&P 500 finished the session 0.02% lower at 1,950.79. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 692.83, up 0.21%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Pharmacyclics Inc. (NASDAQ: PCYC), Amarin Corp. PLC (NASDAQ: AMRN) and Prana Biotechnology Ltd (NASDAQ: PRAN). Free technical research on ISIS, PCYC, AMRN and PRAN can be downloaded upon signing up at:


On Tuesday, shares in Isis Pharmaceuticals Inc. fluctuated between $32.30 and $34.20 before ending the session 9.84% higher at $34.17. The stock reported a trading volume of 5.19 million shares, much above its three months average volume of 2.66 million shares. Isis Pharmaceuticals Inc.'s shares have rallied 12.96% in the previous three sessions and 45.90% in the last one month, while the stock has lost 14.23% on YTD basis. The stock is trading above its 50-day moving average of $30.89, while the 50-day moving average is below its 200-day moving average of $37.71. Moreover, shares of Isis Pharmaceuticals Inc. have a Relative Strength Index (RSI) of 57.98. On the same day, Isis Pharmaceuticals Inc. announced that AstraZeneca has initiated a Phase 1 clinical study of its antisense drug, ISIS-ARRx in patients with cancer. The company has also received payment of $15 million in association with the clinical advancement of ISIS-ARRx. Sign up today to read free research on ISIS at:


On Tuesday, Pharmacyclics Inc.'s stock edged 0.42% lower, to close the day at $96.67. The stock recorded a trading volume of 1.07 million shares, below its three months average volume of 1.59 million shares. The stock oscillated between $94.19 and $98.78 during the session. Over the last three trading sessions and over the past one month, Pharmacyclics Inc.'s shares have gained 2.77% and 1.67%, respectively. However, the stock has lost 8.61% since the start of this year. The stock is trading above its 50-day moving average of $94.77, while the 200-day moving averages of $117.33 is above its 50-day moving average. Additionally, Pharmacyclics Inc.'s stock traded at a PE ratio of 54.93 and has an RSI of 54.58. Sign up today to read free research on PCYC at:


On Tuesday, shares in Amarin Corp. PLC recorded a trading volume of 0.85 million shares, lower than its three months average volume of 1.90 million shares. The stock ended the day at the previous day's closing price of $1.50, and registered an intraday range of $1.49 and $1.52. Although Amarin Corp. PLC's stock has gained 4.17% in the previous three trading sessions, it has lost 0.66% in the last one month and 23.86% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $1.57 and $2.67, respectively. Furthermore, shares of Amarin Corp. PLC have an RSI of 53.65. Sign up today to read free research on AMRN at:


Prana Biotechnology Ltd's stock finished the Tuesday's session 6.84% higher at $2.03. A total of 1.47 million shares were traded, which was below its three months average volume of 1.98 million shares. The stock vacillated between $1.88 and $2.05 during the session. Over the previous three trading sessions and over the last one month, Prana Biotechnology Ltd's shares have surged 14.69% and 20.83%, respectively. However, from the beginning of 2014, the company's stock has declined 71.04%. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $5.48 is greater than its 50-day moving average of $2.02. Shares of Prana Biotechnology Ltd have an RSI of 45.98. Sign up today to read free research on PRAN at:


=============== EDITOR'S NOTES: ===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

share with twitter share with LinkedIn share with facebook
share via e-mail
11/14 Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite S..
11/13 Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid..
11/13 Real-World Data Analysis Shows That High Triglyceride Levels Are Associated W..
11/07 Amarin to Present at the Jefferies London Healthcare Conference
11/01 Amarin Reports Third Quarter 2017 Financial Results and Provides Update on O..
09/25 Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in C..
09/20 Amarin to Present at Cantor Global Healthcare Conference
09/13 Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
09/06 Amarin to Present at Rodman & Renshaw’s Global Investment Conference
08/23 AMARIN : Technical Snapshots for These Drug Makers Stocks -- Teva Pharma, Endo, ..
More news
News from SeekingAlpha
11/15 AMARIN : A Likely Runner In 2018
11/14 Amarin's Vascepa shows treatment effect in CKD patients in late-stage study; ..
11/13 After Hours Gainers / Losers
11/03 Amarin Corporation PLC 2017 Q3 - Results - Earnings Call Slides
11/01 Amarin Corporation's (AMRN) CEO John Thero on Q3 2017 Results - Earnings Call..